PRINT OUT

News Release 2019

November 08, 2019 Presentation Material for IR Meeting <PDF>
November 06, 2019 Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2019 <PDF>
November 06, 2019 (Media)Designation of Oligonucleotides NS-065/NCNP-01(viltolarsen) Subjected to Conditional Early Approval System <PDF>
October 07, 2019 (Media)Morpholino Oligonucleotide NS-065/NCNP-01 (viltolarsen), Presentation on results of an additional analysis of Phase I/II study in Japan <PDF>
October 07, 2019 (Media)Morpholino Oligonucleotide NS-065/NCNP-01 (viltolarsen) Presentation of Phase II Study in the US <PDF>
October 02, 2019 (Media)U.S. FDA Submission of New Drug Application for NS-065/NCNP-01 (viltolarsen) <PDF>
September 26, 2019 (Media)Submission of New Drug Application for NS-065/NCNP-01 (viltolarsen) in Japan <PDF>
September 04, 2019 (Media)Launch of Defitelio® injection 200mg for the treatment of sinusoidal obstruction syndrome (hepatic veno-occlusive disease) <PDF>
August 22, 2019 (Media)NS-065/NCNP-01 (viltolarsen) under development, granted Orphan Drug Designation by MHLW <PDF>
August 07, 2019 Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2019 <PDF>
August 07, 2019 Presentation Material for IR Meeting <PDF>
June 18, 2019 (Media)Marketing approval of Defitelio by MHLW for the treatment of sinusoidal obstruction syndrome / hepatic veno-occlusive disease <PDF>
May 31, 2019 Notice Of The 156th Annual General Meeting Of Shareholders <HTML>
May 24, 2019 Presentation Material for 6th Five-Year Medium-term Management Plan <PDF>
May 22, 2019 (Media)Launch of ERLEADA® (apalutamide) 60mg tablet for the treatment of prostate cancer <PDF>
May 15, 2019 Presentation Material for IR Meeting <PDF>
May 14, 2019 (Media)6th Five-Year Medium-term Management Plan “Aiming for Sustainable Growth -Pursuit of Further Originality-” <PDF>
May 13, 2019 Outline of Consolidated Financial Results for the Year Ended March 31, 2019 <PDF>
May 10, 2019 (Media)Notification of a Contract Concluded for Tadalafil, a Phosphodiesterase-5 Inhibitor <PDF>
April 23, 2019 Revision of Performance Projection and Dividend Forecast <PDF>
March 26, 2019 (Media)MHLW approval of ERLEADA® (apalutamide) 60mg tablet For the treatment for castration-resistant prostate cancer without distant metastases <PDF>
March 25, 2019 (Media)Results of the PHOSPHASE study of iron isomaltoside 1000 in ENDO congress <PDF>
March 19, 2019 (Media)Exclusive Distribution Agreement with Zogenix for ZX008 in Japan <PDF>
February 06, 2019 Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2018 <PDF>
February 06, 2019 Presentation Material for IR Meeting <PDF>
January 21, 2019 (Media) Nippon Shinyaku Co., LTD. signs co-promotion agreement with Janssen for apalutamide <PDF>
get_adobe_reader
page-top